Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intrace...

Full description

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 8; no. 12; pp. 1197 - 1206
Main Authors Voldborg, B. Rude, Damstrup, L., Spang-Thomsen, M., Poulsen, H. Skovgaard
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.12.1997
Subjects
Biological and medical sciences
cancer
Cell receptors
Cell structures and functions
Clinical Trials as Topic
epidermal growth factor receptor
ErbB Receptors - chemistry
ErbB Receptors - genetics
ErbB Receptors - physiology
Fundamental and applied biological sciences. Psychology
Gene Deletion
Hormone receptors. Growth factor receptors. Cytokine receptors. Prostaglandin receptors
Humans
Molecular and cellular biology
Mutation
Neoplasms - genetics
Neoplasms - metabolism
Phenotype
signal
Signal Transduction
tyrosine kinase
Epidermal growth factor
Treatment
Gene product
Tumor progression
Review
Mutation
Malignant tumor
Gene expression
Biological receptor
Online AccessGet full text

Cover

More Information
Summary:The epidermal growth factor receptor (EGFR) is a growth factor receptor that induces cell differentiation and proliferation upon activation through the binding of one of its ligands. The receptor is located at the cell surface, where the binding of a ligand activates a tyrosine kinase in the intracellular region of the receptor. This tyrosine kinase phosphorylates a number of intracellular substrates that activates pathways leading to cell growth, DNA synthesis and the expression of oncogenes such as fos and jun. EGFR is thought to be involved the development of cancer, as the EGFR gene is often amplified, and/or mutated in cancer cells. In this review we will focus on: (I) the structure and function of EGFR, (II) implications of receptor/ligand coexpression and EGFR mutations or overexpression, (III) its effect on cancer cells, (IV) the development of the malignant phenotype and (V) the clinical aspects of therapeutic targeting of EGFR.
Bibliography:ark:/67375/HXZ-21V2KVF2-B
istex:BEBF3EFFD9219C8F0958155FA960706EA740FA28
ArticleID:8.12.1197
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0923-7534
1569-8041
DOI:10.1023/A:1008209720526